Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus

NCT05467514 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication liraglutide could affect early signs of artery hardening in adults with type 1 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 35 people

Who can join Ages 15–60 · all sexes

Timeline Started 2022-07 · est. completion 2023-02

Where 1 site · Mexico

What this study is testing ClinicalTrials.gov NCT05467514 ↗

Description as written by the study sponsor.

The aim of the trail is investigate the effect of liraglutide 1.8mg as add-on to insulin for 6 months on carotid intima media thickness and cardiovascular risk factors in subjects with type 1 diabetes mellitus.

Treatments tested

Liraglutide Drug

Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus

Main thing measured	To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus.
Sponsor	David Sanchez Garcia
Conditions studied	Diabetes Mellitus, Type 1
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05467514 ↗